Robert Cavorsi
Corporate Officer/Principal bij ORGANOGENESIS HOLDINGS INC.
Vermogen: 157 944 $ op 31-05-2024
Profiel
Robert Cavorsi is currently the Vice President-Strategy at Organogenesis Holdings, Inc. He previously worked as the Neurology Director-Sales Operations at Sumitomo Pharma America, Inc. from 2015 to 2016.
He obtained his undergraduate degree from The Pennsylvania State University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
19-04-2024 | 57 434 ( 0.04% ) | 157 944 $ | 31-05-2024 |
Actieve functies van Robert Cavorsi
Bedrijven | Functie | Begin |
---|---|---|
ORGANOGENESIS HOLDINGS INC. | Corporate Officer/Principal | 01-01-2021 |
Eerdere bekende functies van Robert Cavorsi
Bedrijven | Functie | Einde |
---|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Verkoop & Marketing | 01-01-2016 |
Opleiding van Robert Cavorsi
The Pennsylvania State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ORGANOGENESIS HOLDINGS INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Health Technology |